Platinum compounds, compositions, and uses thereof
The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.
1. A pharmaceutical composition comprising Compound 8:
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein the pharmaceutical composition has a pH of about 4 to about 5, wherein the pharmaceutical composition further comprises a citrate buffer, and wherein the pharmaceutically acceptable excipient is mannitol.
2. The pharmaceutical composition of claim 1 , wherein the concentration of Compound 8 is 3-5 mg/mL.
3. The pharmaceutical composition of claim 2 , wherein the concentration of Compound 8 is 5 mg/mL.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition has a pH of about 4 or about 4.25.
5. The pharmaceutical composition of claim 1 , the buffer has a concentration of about 0.5 mM to about 100 mM.
6. The pharmaceutical composition of claim 1 , wherein the citrate buffer comprises sodium citrate and citric acid, or citric acid and sodium hydroxide.
7. The pharmaceutical composition of claim 1 , wherein the excipient has a weight percent of about 0.5% (w/w) to about 20% (w/w).
8. The pharmaceutical composition of claim 1 , wherein the excipient has a weight percent of about 2.5% (w/w).